TaiGen Biopharmaceuticals Holdings (ROCO:4157) Interest Expense : NT$-1.4 Mil (TTM As of Dec. 2024)

View and export this data going back to 2013. Start your Free Trial

What is TaiGen Biopharmaceuticals Holdings Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. TaiGen Biopharmaceuticals Holdings's interest expense for the three months ended in Dec. 2024 was NT$ -0.3 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2024 was NT$-1.4 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. TaiGen Biopharmaceuticals Holdings's Operating Income for the three months ended in Dec. 2024 was NT$ -53.9 Mil. TaiGen Biopharmaceuticals Holdings's Interest Expense for the three months ended in Dec. 2024 was NT$ -0.3 Mil. TaiGen Biopharmaceuticals Holdings did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

TaiGen Biopharmaceuticals Holdings Interest Expense Historical Data

The historical data trend for TaiGen Biopharmaceuticals Holdings's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TaiGen Biopharmaceuticals Holdings Interest Expense Chart

TaiGen Biopharmaceuticals Holdings Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Interest Expense

Get a 7-Day Free Trial

-0.60

-0.24

-0.85

-1.14

-1.42

TaiGen Biopharmaceuticals Holdings Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Interest Expense	Get a 7-Day Free Trial															-0.41	-0.39	-0.37	-0.34	-0.33

TaiGen Biopharmaceuticals Holdings Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-1.4 Mil.

TaiGen Biopharmaceuticals Holdings (ROCO:4157) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

TaiGen Biopharmaceuticals Holdings's Interest Expense for the three months ended in Dec. 2024 was NT$-0.3 Mil. Its Operating Income for the three months ended in Dec. 2024 was NT$-53.9 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2024 was NT$42.4 Mil.

TaiGen Biopharmaceuticals Holdings's Interest Coverage for the quarter that ended in Dec. 2024 is calculated as

TaiGen Biopharmaceuticals Holdings did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

TaiGen Biopharmaceuticals Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TaiGen Biopharmaceuticals Holdings Ltd (ROCO:4157) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 138 Xinming Road, 7th Floor, Neihu District, Taipei, TWN, 114

Website

https://www.taigenbiotech.com/tw

TaiGen Biopharmaceuticals Holdings Ltd is mainly engaged in the research and development of new drugs, including the selection of drug candidates, pre-IND trials and clinical trials. Its operating segment includes development, research and sales of new drugs, and other.

TaiGen Biopharmaceuticals Holdings Headlines

No Headlines